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Abstract  
 
Cyclizine is a piperazine derivative with anti-emetic activity that is useful in the 
prevention and treatment of nausea and vomiting associated with motion sickness. A 
liquid chromatography-tandem mass spectrometry (LC-MS-MS) method is presented for 
the quantitation of cyclizine in serum. Sample pretreatment involved liquid-liquid 
extraction of 200 µl of serum with dichloromethane after the addition of 100 µl each of 
ammonium hydroxide and internal standard solutions. The extracts were analyzed by 
HPLC on a Luna 
® 
C
18 
reversed-phase column and an ion-trap mass spectrometer with an 
electrospray interface.  
 
A limit of detection of 1 ng/ml was determined which allowed for the reliable 
measurement of cyclizine in the serum of human subjects. The method was found to be 
linear over the calibration range of 2.5-100 ng/ml. The applicability of this method was 
demonstrated by the analysis of serum obtained from a human volunteer following 
administration of a single 50 mg cyclizine hydrochloride tablet. The reported method was 
observed to have the necessary sensitivity, selectivity, precision and accuracy for 
monitoring cyclizine concentrations in human subjects following oral administration.  
 
 
1. Introduction  
 
Cyclizine (CYC), 1-(diphenylmethyl)-4-methylpiperazine or 1-benzhydryl-4-
methylpiperazine [1] is a piperazine derivative that has been effectively used for the 
prevention and treatment of nausea and vomiting associated with motion sickness [2] and 
[3]. The structures of CYC and chlorcyclizine (CLCYC), the internal standard, are shown 
in Fig. 1. 
 
 
 
Fig. 1. Chemical structures of cyclizine (MW = 266.40) and chlorcyclizine (MW = 
301.90). 
 
The analysis of drugs in biological fluids requires an accurate, sensitive, selective and 
precise analytical technique to ensure a valid representation of the drug's absorption and 
disposition in the body. 
 
Assay methods for CYC in both serum and urine have used colorimetric detection 
methods [4], derivatization with tritiated acetic anhydride [5], gas–liquid chromatography 
[6] and [7], GC–MS [8] and [9] and HPLC with ultraviolet detection [10] and [11]. 
Limitations of some of these methods include the lack of the requisite sensitivity and 
selectivity necessary for accurate assessment of the pharmacokinetics of the drug. In 
addition, large sample volumes and complex procedures such as the use of derivatization 
techniques result in the need to harvest inordinately large volumes of blood samples and 
tedious and extended sample preparation times. Subsequently an HPLC method with the 
requisite sensitivity using dual-electrode coulometric detection in the “oxidative-screen 
mode” was published in 1995 [12]. However, this method also requires a complex and 
time-consuming solid-phase extraction procedure followed by a micro phase-separation 
step to prepare samples for analysis. The current method has the requisite sensitivity, 
selectivity, accuracy and precision for the determination of CYC in serum, offers a rapid 
and simple sample pretreatment which requires only 200 µl of serum and includes an 
improved extraction procedure compared to those previously reported [12].  
 
In recent years, the use of LC–MS–MS in biomedical research [13] and more specifically 
for the quantitative determination of drugs in biological fluids [14] has increased 
exponentially. More recently a method for screening and quantitation of a range of 
antihistaminic drugs in blood by LC–MS has been published [15]. Whilst the sensitivity 
is comparable to that reported using HPLC-UV [11], the recovery of CYC was reported 
to be an unusually high value of 137%.  
 
Development of techniques such as electrospray and atmospheric pressure chemical 
ionization (APCI) has largely contributed to the success of this technique, particularly in 
combination with HPLC and the application of LC–MS–MS with associated advantages 
of high specificity and greater sensitivity [16]. The advantages offered by LC–MS–MS 
coupled with a “micro-sample” liquid–liquid extraction method were therefore applied 
for the successful quantitative determination of CYC in human serum using CLCYC as 
an internal standard.  
 
2. Experimental  
 
2.1. Reagents and chemicals  
 
CYC hydrochloride BP (CYC) was obtained from Lennon Ltd. Laboratories, South 
Africa and the internal standard, CLCYC hydrochloride (CLCYC) was obtained from the 
Wellcome Foundation Ltd., United Kingdom. 
 
HPLC grade acetonitrile (Romil Ltd., Cambridge, United Kingdom), formic acid (99%) 
(Associated Chemical Enterprises, (Pty), Ltd., Johannesburg, South Africa) and aqueous 
ammonium hydroxide solution (25%, w/v) (Protea Laboratory Services, Port Elizabeth, 
South Africa) were of analytical reagent grade and were used without additional 
purification. 
 
All other chemicals and reagents were of analytical grade and HPLC grade water was 
obtained by reverse osmosis and filtration through a Milli-Q system (Millipore, Milford, 
MA, USA) and was used to prepare all solutions. 
 
Valoid
® 
(GlaxoWellcome, South Africa) tablets having a label claim of 50 mg CYC as 
the hydrochloride which corresponds to 44 mg of CYC free-base, were purchased from a 
local pharmacy. 
 
Drug free human serum was obtained from the South African blood transfusion service 
(Port Elizabeth, South Africa). 
 
2.2. Equipment and LC–MS–MS conditions  
 
A modular HPLC system consisting of a Spectraphysics Spectra System P2000 pump, an 
AS 3000 autosampler (Thermo Separation Products, San Jose, CA, USA) and a Finnigan 
Matt LCQ ion-trap mass spectrometer with an electrospray interface (San Jose, CA, 
USA) was used for the LC–MS–MS analysis.  
 
Chromatographic separation was achieved using a Phenomenex, Luna
® 
C
18
(2) 5 µm (150 
mm × 2 mm), reversed-phase minibore analytical column (Torrance, CA, USA). The 
analysis was performed with a mobile phase consisting of 0.2% (v/v) formic acid in water 
(adjusted to pH 4 with ammonium hydroxide solution):acetonitrile (65:35, v/v) using a 
flow rate of 0.2 ml/min at 30 °C and an injection volume of 20 µl. An Upchurch 
Scientific Uptight Precolumn Kit (Oak Harbor, WA, USA) packed with glass beads, was 
used as a guard column.  
 
Positive ion electrospray ionisation (ESI) mass spectrometry was performed on CYC and 
CLCYC. The MS parameters were optimised separately by direct infusion of a solution 
of each analyte (1 µg/ml) into the source at a rate of 5 µl/min, without splitting. The use 
of two segments during the chromatographic run made scanning at optimum conditions 
possible.  
 
The protonated molecular ions [M + H]
+ 
at m/z 267 (CYC) and m/z 301 (CLCYC) were 
initially monitored in the full scan mode between m/z 80 and m/z 350 using an isolation 
width 
of 5 amu for each ion. The HPLC eluate entered the mass spectrometer at a source 
voltage of 4.5 kV whilst the capillary temperature was maintained at 200 °C. The 
capillary voltage was set at 17 and 11.5 V for CYC and CLCYC, respectively, whilst the 
sheath to auxiliary gas ratio was set at 4:1. MS–MS experiments were subsequently 
undertaken through collision induced dissociation of the parent molecules (26% for CYC; 
25% for CLCYC) and the resulting product ion was used for diagnostic confirmation. 
 
2.3. Preparation of standard and quality control (QC) samples  
 
Primary standard stock solutions of CYC (1 mg/ml) and CLCYC (1 mg/ml) as the 
hydrochloride salt, were prepared by dissolving an accurately weighed quantity of each 
compound equivalent to 20 mg of free base in water. In all cases, the solutions were 
protected from light using aluminium foil and stored at 4 °C during these studies. Serum 
standard (100 ng/ml) and QC (100 ng/ml) stock solutions were prepared by spiking drug 
free serum with known aliquots of an appropriate dilution of an aqueous CYC solution 
(20 µg/ml). Serum calibration standard solutions over the concentration range from 2.5 to 
100 ng/ml with the exception of the upper concentration (100 ng/ml) were prepared by 
spiking drug free serum with known aliquots of serum standard stock solution, followed 
by extraction. QC samples of 5, 20 and 80 ng/ml were prepared by spiking drug free 
serum with known aliquots of the QC stock solution of CYC (100 ng/ml). Aliquots (2 ml) 
of the QC samples and calibration standards were pipetted into 5 ml non-sterile 
polystyrene blue cap tubes and stored at −20 °C until required for use. 
 
 
 
2.4. Extraction procedure  
 
For the determination of cyclizine, 100 µl ammonium hydroxide (25%, v/v) and 100 µl 
aqueous internal standard solution (200 ng/ml) were added to two hundred microlitres 
(200 µl) of serum samples. The mixture was vortexed for 30 s after which 2 ml 
dichloromethane was added and vortexed for a further minute. The mixture was 
centrifuged at 6000 rpm for 3 min to separate the aqueous and organic layers. After 
removal of the organic layer the extraction was repeated on the residual aqueous layer.  
 
The dichloromethane layers were pooled and dried at 40 °C under a gentle stream of 
nitrogen using an N-Evap
® 
Model 112 analytical evaporator (Organomation Associates 
Inc., South Berlin, MA, USA). After drying, samples were reconstituted with100 µl of 
HPLC mobile phase, vortexed for 1 min and centrifuged at 6000 rpm, for 2 min and a 20 
µl aliquot of the reconstituted sample was injected onto the chromatographic system. 
 
2.5. Calibration and system validation  
 
Calibration curves were constructed by plotting peak area ratios of CYC and internal 
standard against CYC concentration and analysis of linearity was performed, over three 
consecutive days, by a 1/× weighted linear regression method using LCQAN
®
, a 
quantitation software package supplied with the mass spectrometer.  
 
The standard curve for CYC incorporated 2.5, 5, 10, 25, 50 and 100 ng/ml with analysis 
of linearity from eight separate assays. The limits of quantitation (LOQ) for the assay was 
defined as the lowest concentration that could be measured with percent relative standard 
deviation (%R.S.D.) (precision) and percent relative error (%R.E.) (accuracy) of <20% as 
determined from spiked serum samples from eight separate assays.  
The limits of detection (LOD) for the assay was defined as the lowest concentration of 
CYC that gave a signal-to-noise ratio of 3.  
 
Reproducibility of the assay was assessed using the QC samples prepared as previously 
described in Section 2.3. A minimum of eight replicates per concentration were analyzed 
for both intra-assay and inter-assay precision, the latter being carried out on different 
days.  
Recovery studies were carried out by adding internal standard at the reconstitution stage 
only, that is, the internal standard was not subjected to the extraction procedure. CYC 
recovery was determined at concentrations of 5, 20 and 80 ng/ml with five replicates at 
each concentration, by comparing the peak area ratios of CYC to CLCYC where the 
CLCYC was added after the extraction step, to the same area ratio for an equivalent 
aqueous sample (un-extracted). Recovery of the internal standard (CLCYC) was assessed 
in the same manner at a concentration of 200 ng/ml.  
 
Stability of CYC in serum was determined from serum QC samples of 5, 20 and 80 ng/ml 
stored at 4 °C for 60 h. Post-extraction stability was determined by extracting QC 
samples at 5, 20 and 80 ng/ml and then left in the autosampler at ambient temperature for 
24 h prior to LC–MS–MS analysis.  
 
Freeze-thaw stability was tested with aliquots of spiked serum at concentrations of 5, 20 
and 80 ng/ml, which were subjected to three freeze-thaw cycles prior to analysis. 
 
 
 
2.6. Application of method  
 
In order to assess the utility of this method for pharmacokinetic studies, a healthy 
volunteer was given a single Valoid
® 
tablet following ethical approval by the Rhodes 
University Ethics Committee. Blood samples were collected at 2- and 4-h after 
administration. The blood was left to stand and the serum harvested for analysis using the 
method described and samples were extracted in duplicate.  
 
3. Results and discussion  
 
An LC–MS–MS assay was developed and validated to enable the quantitative analysis of 
CYC in serum samples.  
 
The electrospray ionization of CYC and CLCYC produced the abundant protonated 
molecular ions [M + H]
+ 
at m/z 266.8 and 300.8, respectively, under positive ionization 
conditions, without any evidence of fragmentation. The full scan ESI mass spectrum of 
the protonated molecular ions of CYC and CLCYC is shown in Fig. 2. Collision induced 
dissociation of these ions resulted in the loss of the methylated piperazine moiety [M − 
100]
+ 
thereby producing fragment ions at m/z 167 and 201 for CYC and CLCYC, 
respectively (Fig. 3B and C). The quantification of the analytes was performed in MS–
MS mode by monitoring both the protonated and product ions and interpolating the 
concentration from the peak area ratios (CYC/IS). 
 
 
 
Fig. 2. Full scan mass spectrum showing the protonated molecular ion of (A) cyclizine 
and (B) chlorcyclizine (internal standard). 
 
 
 
 
Fig. 3. (A) HPLC–MS–MS chromatogram of a serum sample obtained from a human 
volunteer 2-h after administration of a 50 mg cyclizine hydrochloride tablet showing 
cyclizine (6.83 min) and chlorcyclizine (10.9 min), (B) product ion mass spectrum of 
cyclizine, (C) product ion mass spectrum of chlorcyclizine. 
 
Examination of linearity over the concentration range 2.5–100 ng/ml yielded a slope of 
0.0254, an intercept of 0.0225 and a correlation coefficient of 0.9994 from eight separate 
assays. The percent relative standard deviation (%R.S.D.) values ranged from 1.16 to 
6.5%.  
The LOQ for the assay was 2.5 ng/ml with a corresponding %R.S.D. of 2.6 and a %R.E. 
of 12.2 and the LOD for CYC was 1 ng/ml. 
 
Intra-assay precision yielded %R.S.D. values ranging from 3.0 at a concentration of 5 
ng/ml to 2.7 at 80 ng/ml, with percent relative errors of 12.2, 1.9 and 6.2 at 5, 20 and 80 
ng/ml respectively (n = 8). Percent R.S.D. values for the inter-assay precision studies 
were 4.8 at 5 ng/ml, 5.1 at 20 ng/ml and 3.5 at 80 ng/ml, with percent relative errors of 
11.0, 3.2 and 6.5, respectively (n = 8) (Table 1). 
 
 
 
 
 
 
 
 
 
Table 1. Intra- and inter-assay precision and accuracy data  
 
Adde
d 
(ng/ml
)  
Intra-assay precision (n 
= 8)  
Inter-assay precision (n 
= 8)  
Found  R.S.D. (%)  
R.E. 
(%)  Found  
R.S.D. 
(%)  
R.E. 
(%)  
5  4.4 ± 0.1  3.0  12.2  
4.5 ± 
0.2  4.8  11.0  
20  20.4 ± 0.4  1.7  1.9  
20.6 ± 
1.0 5.1  3.2  
80  85.0 ± 2.3  2.7  6.2  
85.2 ± 
3.0 3.5  6.5  
 
 
Data expressed as mean ± S.D. for “found” values and mean data shown for %R.E. 
 
CYC recovery rates were assessed by comparison of peak area ratios of aqueous standard 
solutions of CYC and samples to which internal standard was added after completion of 
the extraction (n = 5). The recovery rates were 74.7 ± 4.7% (mean ± S.D.), 86.3 ± 1.5 and 
79.4 ± 1.9% with %R.S.D. values of 6.3, 1.7 and 2.1% at 5, 20 and 80 ng/ml, 
respectively, with an overall mean recovery of CYC 80.1 ± 2.8% (Table 2). The recovery 
of the internal standard, CLCYC (200 ng/ml) was 72.5 ± 1.6% (mean ± S.D.; n = 5). 
 
Table 2. Absolute recovery rates following extraction  
 
Added 
(ng/ml)  
Recovery 
(ng/ml)  R.S.D. (%) 
Recovery 
(%)  
5  3.7 ± 0.2  6.3  74.7 ± 4.7  
20  17.3 ± 0.3  1.7  86.3 ± 1.5  
80  63.5 ± 1.5  2.4  79.4 ± 1.9  
 
 
Data obtained from five replicates at each concentration. Recovery data expressed as 
mean ± S.D. 
 
Stability of the QC serum samples evaluated at 4 °C indicated that the drug was stable for 
a period of 60 h (Table 3). Post-extraction stability of samples left in the autosampler at 
room temperature indicated a loss of <10% at the 20 and 80 ng/ml concentrations and 
<15% at the 5 ng/ml concentration. Exposure of spiked serum samples to three freeze-
thaw cycles prior to extraction had no significant effect on the analysis of CYC where the 
%R.E. ranged from 8.8 at 5 ng/ml to <2 for the 20 and 80 ng/ml concentrations. 
 
 
 
 
 
 
 
Table 3. Stability of spiked QC serum samples stored at 4 °C for 60 h  
 
Concentratio
n (ng/ml)  R.S.D. (%)  
Interpolated 
concentration R.E. (%)  
5  3.5  5.1 ± 0.2  2.7  
20  1.5  22.1 ± 0.3  10.3  
80  1.9  82.9 ± 1.6  3.7  
 
Data obtained from five replicates at each concentration. 
 
Analysis of serum samples obtained from a healthy volunteer who was administered a 
Valoid
® 
tablet (50 mg CYC hydrochloride) after an overnight fast indicated that this 
assay is readily applicable for the quantitative analysis of cyclizine in serum samples.  
Fig. 3 A depicts a representative chromatogram obtained by LC–MS–MS analysis of a 
serum sample obtained from a human volunteer 2-h after oral administration of CYC. 
The analysis of blank serum samples did not show any interference at the retention times 
of CYC and CLCYC confirming the specificity of this method. Table 4 depicts the serum 
concentrations found in the subject at 2 and 4 h post administration. 
 
Table 4. CYC concentration following single oral dose administration  
 
Time after 
administration (h)  R.S.D. (%)  
Concentration 
(ng/ml) (n = 5)  
2  4.3  36.7 ± 1.6  
4  2.6  77.1 ± 2.0  
 
Concentration data expressed as mean ± S.D. and mean data are shown for %R.S.D. 
 
Reported blood levels for CYC following intravenous administration of 50 mg CYC 
lactate to a single volunteer was approximately 300 ng/ml [6] and between 50 and 105 
ng/ml in six human subjects following a 25 mg dose [17] and extraction of 1 ml aliquots 
of serum. The concentrations of CYC found in the serum of the subject used in this study, 
in which only a 200 µl sample was used are similar to those obtained in human studies in 
which the peak concentrations in plasma and serum after oral administration were 69 
ng/ml [7] and 80 µg/ml using a 2 ml serum aliquot [8] and 57 ng/ml using a 1 ml sample 
[11].  
 
The combination of tandem mass spectrometry with HPLC has proved extremely suitable 
for the highly specific quantitative and accurate measurement of CYC in serum.  
 
An LC–MS–MS method [15] previously reported the quantitation of CYC with a LOQ of 
5 ng/ml which was associated with a high recovery of 137%. This suggests that the LOQ 
was somewhat higher than 5 ng/ml possible due to the contribution of matrix effects. 
 
4. Conclusion  
 
The method reported in this paper describes a sensitive, selective and accurate LC–MS–
MS method for the determination of CYC in human serum and offers a rapid and simple 
sample pretreatment requiring only 200 µl of serum compared to previously reported 
methods where 1 or even 2 ml samples were used. Clearly this implies that should lower 
concentrations need to be monitored, a larger sample volume could be used. Furthermore, 
the extraction procedure was more efficient than previously reported [12] and yielded 
reliable values [15].  
 
The proposed method has the requisite sensitivity, accuracy and precision for the 
determination of CYC in serum and is readily applicable for 
bioavailability/bioequivalence and pharmacokinetic studies. 
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